Start the conversation
Leave a Reply
You must be logged in to post a comment.
The VRX stock price plunged 10.5% yesterday (Monday), marking one of the stock's worst single-day performances of the year.
On Monday, shares of Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped after CEO J. Michael Pearson took a medical leave of absence due to severe pneumonia. Valeant's board created both a three-man chief executive office to temporarily lead the company and a committee to oversee the office.
Pearson has headed the pharmaceutical giant since 2008 and has been at the center of the firm's numerous controversies this year. Back in September, Valeant came under fire for hiking the prices of two commonly used heart drugs - Nitropress and Isuprel - by 212% and 525%, respectively. The move outraged congressional Democrats, who urged the House Committee on Oversight and Government Reform to subpoena Pearson to testify on the price gouging.
Valeant's second blow came in October when Citron Research reported Valeant used its partner pharmacy, Philidor, to steer customers toward buying expensive drugs sold by Valeant. Citron called Valeant the "pharmaceutical Enron" in the report. This led several pharmacy benefits managers to sever ties with the company.
As a result, the VRX stock price has plummeted 57.8% since Sept. 18. It has fallen nearly 43% in just the fourth quarter alone.
With VRX stock down another 1.5% and trading just above $100 a share today (Tuesday), investors are wondering if the stock is bottoming out and ready to move higher next year...
Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter
Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…